1-(1H-苯并咪唑-2-基)-1-丙酮 | 74126-96-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1-(1H-苯并咪唑-2-基)-1-丙酮
• 英文名称: 2-propionylbenzimidazole
• 英文别名: 1-(1H-Benzo[d]imidazol-2-yl)propan-1-one；1-(1H-benzimidazol-2-yl)propan-1-one
• CAS: 74126-96-8
• 化学式: C₁₀H₁₀N₂O
• mdl: MFCD18811105
• 分子量: 174.202
• InChiKey: ZNCIRTDOBZGUMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(1H-苯并咪唑-2-基)-1-丙酮 在 sodium hydride 作用下， 以 1,4-二氧六环 、 盐酸 为溶剂， 反应 2.0h， 生成 1-[1-(2,3-Dihydroxy-propyl)-1H-benzoimidazol-2-yl]-propan-1-one
  参考文献：
  名称：

  Dostert; Langlois; Guerret, European Journal of Medicinal Chemistry, 1980, vol. 15, # 3, p. 199 - 205

  摘要：

  DOI：
• 作为产物：
  描述：

  (9ci)-alpha-乙基-1H-苯并咪唑-2-甲醇 在 manganese(IV) oxide 作用下， 以48%的产率得到1-(1H-苯并咪唑-2-基)-1-丙酮
  参考文献：
  名称：

  Dostert; Langlois; Guerret, European Journal of Medicinal Chemistry, 1980, vol. 15, # 3, p. 199 - 205

  摘要：

  DOI：

文献信息

• NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：Yoshida Tomohiro

  公开号：US20100228026A1

  公开（公告）日：2010-09-09

  The invention provides a sulfonyl malonamide derivative, or a pharmacologically acceptable salt thereof or a solvate thereof, that has therapeutic and/or preventive effect(s) on various diseases due to its agonist action at AT 2 receptor, and is useful as a pharmaceutical agent for the treatment and/or prevention of diseases involving the renin-angiotensin-aldosterone system (RAAS).

  该发明提供了一种磺酰基马隆酰胺衍生物，或其药理学上可接受的盐或溶剂，由于其在AT2受体上的激动剂作用，对各种疾病具有治疗和/或预防作用，并且作为用于治疗和/或预防涉及肾素-血管紧张素-醛固酮系统（RAAS）疾病的药物剂形具有用处。
• Improvements in or relating to benzimidazoles
  申请人：ELI LILLY AND COMPANY

  公开号：EP0111993A2

  公开（公告）日：1984-06-27

  Certain N-substituted benzimidazoles, which are potent antiviral agents, are disclosed. The compounds are prepared by reacting the corresponding keto derivative with an alkylating agent or by cyclizing the corresponding o-phenylenediamine. Pharmaceutical formulations containing such compounds and a method of treating viral infections are provided.

  本研究公开了某些 N-取代的苯并咪唑，它们是有效的抗病毒剂。这些化合物是通过使相应的酮衍生物与烷化剂反应或使相应的邻苯二胺环化而制备的。还提供了含有此类化合物的药物制剂和治疗病毒感染的方法。
• (3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP2316824A1

  公开（公告）日：2011-05-04

  The present invention relates to (3-amino-1,2,3,4-tetrahydro-9H-carbazol-9-yl)-acetic acid derivatives of Formula I wherein R1, R2, R3, R4, R5 and R6 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

  本发明涉及式 I 的（3-氨基-1,2,3,4-四氢-9H-咔唑-9-基）-乙酸衍生物 其中R1、R2、R3、R4、R5和R6如说明书所述，以及它们作为前列腺素受体调节剂，特别是作为前列腺素D2受体调节剂在治疗各种前列腺素介导的疾病和失调中的用途，还涉及含有这些化合物的药物组合物及其制备工艺。
• Inhibitors of cysteine proteases and methods of use thereof
  申请人：Pardes Biosciences, Inc.

  公开号：US11312704B2

  公开（公告）日：2022-04-26

  The disclosure provides compounds, such as compounds of Formula II, with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.

  本公开提供了具有弹头的化合物，如式 II 化合物，以及它们在治疗医学疾病或紊乱（如病毒感染）中的用途。还提供了药物组合物和制造各种带弹头化合物的方法。这些化合物被认为可抑制蛋白酶，如 3C、CL- 或 3CL 样蛋白酶。
• TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160152627A1

  公开（公告）日：2016-06-02

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.